Acrivon Therapeutics (NASDAQ:ACRV) just reported results for the first quarter of 2024.
- Acrivon Therapeutics reported earnings per share of -73 cents. This was above the analyst estimate for EPS of -84 cents.
- The company did not report any revenue for the quarter.